What it takes to leverage AI in pharma and biotech R&D
In March 2024 John Rountree, Managing Director of Novasecta, facilitated Chatham-House-Rules discussion for senior executives in the biotech and pharmaceutical sectors, focusing on how firms can make the most of (Artificial Intelligence) AI for their Research and Development (R&D) efforts. This report summarises insights from the workshop. With transparency, realism, and a truly multi-disciplinary and […]
5 Imperatives for Strategic And Operational Excellence: #1 Strategic Focus
Developing and maintaining a sharp strategic focus is a must for strategic and operational excellence in pharma and biotech. In part one of our series ‘The Five Imperatives of Strategic and Operational Excellence’, we explore why strategic focus is important, what good looks like, and how a sharp strategic focus contributes to strategic and operational […]
Novo Nordisk showed ‘extraordinary growth’ but faces competitive weight loss market (CNBC)
John Rountree, Managing Partner at Novasecta, comments on Danish pharma giant Novo Nordisk’s first-quarter earnings. Watch John’s interview here.
Data deals for an AI biotech
Challenge An AI drug discovery biotech sought drug discovery data from both failed and successful assets to train its algorithms. Management wanted to understand MidPharma appetite for and concerns over providing their drug discovery data in creative deal structures, so that it could consider how to further evolve its data strategy. Solution Engaged with the […]